# Velabs Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/velabs-therapeutics

- Industry: Biotechnology
- Headquarters: Heidelberg, Germany
- Website: www.velabs-therapeutics.com
- Total disclosed funding: $3.4M
- Latest round: Series B (Jun 11, 2019)
- Investors on record: 2

## About

Velabs Therapeutics GmbH is a biotechnology firm focused on developing innovative biotherapeutic products to meet unmet medical needs, particularly in oncology and autoimmune disorders.Founded in 2017 in Heidelberg, Germany, Velabs Therapeutics GmbH develops biotherapeutic solutions aimed at improving patient care. The company raised EUR 3.00 mn in Series B funding on June 11, 2019, led by Vertex One Asset Management alongside EMBLEM Technology Transfer. Christoph Merten, the founder, has a strong background in biotechnology, although no other ventures are mentioned.Velabs Therapeutics specializes in developing biotherapeutic products that address unmet medical needs across various therapeutic areas. Their offerings include monoclonal antibodies and protein-based therapeutics targeting specific diseases, particularly in oncology and autoimmune disorders. These products are intended for use by healthcare providers, including hospitals and specialty clinics, to enhance patient care. Velabs Therapeutics maintains a global client base that spans North America, Europe, and parts of Asia, expanding their impact on patient health.Revenue for Velabs Therapeutics is generated through direct sales of therapeutic products and strategic partnerships with healthcare organizations. The company engages in B2B transactions, supplying healthcare providers with biotherapeutics for advanced treatment options. Revenue structures involve negotiated contracts, including bulk purchasing and long-term supply agreements, with pricing reflecting the value provided, thus supporting sustainable growth in their revenue model.Looking ahead, Velabs Therapeutics aims to launch new therapeutic products designed to address specific medical needs within the next two years. The recent Series B funding of EUR 3.00 mn will support the development and potential market entry of these products. Additionally, the company plans to expand into markets in Asia and North America, targeting a broader client base by 2022, thereby increasing their global footprint.

## Funding rounds

- Series B, Jun 11, 2019, $3.4M — Vertex One Asset Management, EMBLEM Technology Transfer

## Investors

- Vertex One Asset Management — Series B
- EMBLEM Technology Transfer (https://capitalatlas.ai/funds/emblem-technology-transfer) — Series B